How should I treat a 34-year-old woman with severe vitamin D deficiency (25-hydroxyvitamin D ≈ 14 ng/mL) and low ferritin (≈ 12 ng/mL)?

Treatment of Vitamin D Deficiency and Iron Deficiency in a 34-Year-Old Woman

For this patient with vitamin D 14.1 ng/mL and ferritin 12 ng/mL, initiate oral cholecalciferol 50,000 IU once weekly for 12 weeks alongside oral ferrous sulfate 325 mg once daily (or 325 mg three times daily if tolerated), taken separately to avoid absorption interference.

Vitamin D Deficiency Management

Severity Assessment and Initial Treatment

• A serum 25-hydroxyvitamin D of 14.1 ng/mL represents severe vitamin D deficiency (defined as <20 ng/mL), placing the patient at risk for secondary hyperparathyroidism, bone loss, muscle weakness, and potentially increased infection risk 1, 2, 3.

• The standard loading regimen is cholecalciferol (vitamin D₃) 50,000 IU once weekly for 12 weeks, which is appropriate for severe deficiency below 10–15 ng/mL 1, 4, 5, 2.

• Cholecalciferol (D₃) is strongly preferred over ergocalciferol (D₂) because it maintains serum concentrations longer and has superior bioavailability, particularly with intermittent dosing 1, 5.

Maintenance Phase

• After completing the 12-week loading phase, transition to maintenance dosing of 800–2,000 IU daily (or 50,000 IU monthly, equivalent to ~1,600 IU daily) to sustain levels ≥30 ng/mL 1, 4, 5.

• The target serum 25-hydroxyvitamin D is ≥30 ng/mL for optimal musculoskeletal health, fracture prevention, and fall reduction 1, 4, 3.

Monitoring Protocol

• Recheck serum 25-hydroxyvitamin D 3 months after initiating maintenance therapy to confirm achievement of target levels, as vitamin D has a long half-life and requires this duration to plateau 1, 4, 5.

• Once stable levels ≥30 ng/mL are achieved, annual monitoring is sufficient 1, 4.

Essential Co-Interventions

• Ensure total calcium intake of 1,000–1,200 mg daily from diet plus supplements if needed, as adequate calcium is necessary for vitamin D to exert its bone-protective effects 1, 4, 5, 2.

• Calcium supplements should be taken in divided doses of no more than 600 mg at once for optimal absorption 1.

• Separate calcium and iron supplements by at least 2 hours to prevent absorption interference 1.

Safety Considerations

• Daily vitamin D doses up to 4,000 IU are completely safe for adults; toxicity is rare and typically occurs only with prolonged daily doses >10,000 IU or serum levels >100 ng/mL 1, 4, 6.

• The upper safety limit for serum 25-hydroxyvitamin D is 100 ng/mL 1.

• Never use active vitamin D analogs (calcitriol, alfacalcidol, doxercalciferol, paricalcitol) to treat nutritional vitamin D deficiency, as they bypass normal regulatory mechanisms and markedly increase hypercalcemia risk 1, 5.

---

Iron Deficiency Management

Severity Assessment and Initial Treatment

• A ferritin of 12 ng/mL represents iron deficiency (normal range typically 15–150 ng/mL for women), which can cause fatigue, weakness, and impaired oxygen delivery 7, 8.

• Oral iron supplementation is first-line therapy: ferrous sulfate 325 mg (containing ~65 mg elemental iron) once daily, or three times daily if tolerated and more rapid repletion is needed 7.

• Take iron on an empty stomach (1 hour before or 2 hours after meals) with vitamin C (orange juice) to enhance absorption, though taking with food is acceptable if gastrointestinal side effects occur 7.

Alternative Oral Iron Formulations

• If ferrous sulfate is not tolerated due to gastrointestinal side effects (nausea, constipation, dark stools), consider:
  • Ferrous gluconate 325 mg (containing ~36 mg elemental iron) once to three times daily
  • Polysaccharide iron complex 150 mg once daily
  • Lower-dose ferrous sulfate (e.g., 325 mg every other day) 7

When to Consider Intravenous Iron

• Intravenous iron (e.g., iron sucrose) is reserved for:

  • Documented oral iron intolerance or malabsorption
  • Chronic kidney disease with ongoing losses
  • Need for rapid repletion (e.g., severe anemia with hemoglobin <8 g/dL)
  • Inflammatory bowel disease or post-bariatric surgery with malabsorption 7, 8

• For this 34-year-old woman without these conditions, oral iron is appropriate initial therapy 7.

Monitoring Protocol

• Recheck complete blood count and ferritin after 3 months of oral iron therapy to assess response 7.

• Expected response includes:

  • Reticulocyte count increase within 1–2 weeks
  • Hemoglobin increase of ~1 g/dL per month
  • Ferritin normalization (>30 ng/mL) within 3–6 months 7

• Continue iron supplementation for 3–6 months after ferritin normalizes to replete iron stores 7.

Critical Pitfalls to Avoid

• Do not take iron and calcium supplements together, as calcium inhibits iron absorption; separate by at least 2 hours 1.

• Do not take iron with proton pump inhibitors, H2 blockers, or antacids, as gastric acid is required for iron absorption 7.

• Do not assume intravenous iron is superior to oral iron in the absence of malabsorption or intolerance; oral therapy is effective and safer for most patients 7, 8.

• Do not forget to investigate the underlying cause of iron deficiency in a premenopausal woman—consider menorrhagia, gastrointestinal blood loss, dietary insufficiency, or malabsorption 7.

---

Practical Implementation Algorithm

Week 0 (Initiation)

1. Start cholecalciferol 50,000 IU once weekly (e.g., every Sunday morning with breakfast) 1, 5, 9.
2. Start ferrous sulfate 325 mg once daily (e.g., every morning on an empty stomach with orange juice, or with food if GI upset occurs) 7.
3. Ensure calcium intake 1,000–1,200 mg daily from diet (dairy, fortified foods) plus supplements if needed, taken separately from iron (e.g., calcium at bedtime) 1, 4.

Week 12 (End of Loading Phase)

1. Transition vitamin D to maintenance: cholecalciferol 1,000–2,000 IU daily (or 50,000 IU monthly) 1, 4, 5.
2. Continue ferrous sulfate 325 mg daily 7.

Month 3 (First Follow-Up)

1. Recheck serum 25-hydroxyvitamin D (goal ≥30 ng/mL) 1, 4, 5.
2. Recheck complete blood count and ferritin (goal ferritin >30 ng/mL, hemoglobin normalized) 7.
3. Adjust vitamin D maintenance dose if level <30 ng/mL (increase to 2,000 IU daily) 1, 4.
4. Continue iron supplementation even if ferritin normalizes, for an additional 3–6 months to replete stores 7.

Month 6–9 (Second Follow-Up)

1. Recheck ferritin to confirm sustained repletion (goal >30 ng/mL) 7.
2. Discontinue iron supplementation if ferritin remains normal and underlying cause addressed 7.
3. Continue vitamin D maintenance indefinitely 1, 4.

Annual Follow-Up

1. Recheck serum 25-hydroxyvitamin D annually to ensure sustained adequacy 1, 4.
2. Recheck ferritin annually if risk factors for recurrent deficiency persist (e.g., heavy menstrual bleeding) 7.

---

Common Pitfalls and How to Avoid Them

• Failing to use a high enough vitamin D loading dose: 50,000 IU weekly for 12 weeks is required for severe deficiency (<15 ng/mL); lower doses (e.g., 1,000–2,000 IU daily) will take many months to normalize levels 1, 5.

• Stopping vitamin D after the loading phase: maintenance therapy is essential to prevent recurrence; most patients require 800–2,000 IU daily indefinitely 1, 4, 5.

• Taking iron and calcium together: this reduces iron absorption by up to 50%; separate by at least 2 hours 1.

• Discontinuing iron too early: continue for 3–6 months after ferritin normalizes to fully replete iron stores 7.

• Not investigating the cause of iron deficiency: in a 34-year-old woman, consider menorrhagia (most common), gastrointestinal blood loss, dietary insufficiency, or malabsorption 7.

• Using active vitamin D analogs: calcitriol and similar agents do not correct 25-hydroxyvitamin D levels and increase hypercalcemia risk; they are reserved for advanced chronic kidney disease with impaired 1α-hydroxylase activity 1, 5.

• Measuring vitamin D levels too early: wait 3 months after starting maintenance therapy to allow levels to plateau; earlier testing does not reflect steady-state and may lead to inappropriate dose adjustments 1, 4.